

Phase 1 Trial: CSD241701

Submission date 17/11/2024	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 18/11/2024	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 18/11/2024	Condition category Other	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Public

Contact name

Ms Gwyn Gibson

Contact details

401 N. Main Street
Winston-Salem
United States of America
27101
+1 336-259-1200
gibsona1@jrta.com

Type(s)

Scientific

Contact name

Dr Gregory Tarleton

Contact details

990 Dulin Road
Mocksville
United States of America
27028
+1 336-413-1542
curedfour@protonmail.com

Type(s)

Principal investigator

Contact name

Dr Devinda Weeraratne

Contact details

22-24 Lisburn Road

Belfast

United Kingdom

BT9 6AD

+44 (0)2890 554047

devinda.weeraratne@celerion.com

Additional identifiers**Integrated Research Application System (IRAS)**

344408

Protocol serial number

CSD241701

Study information**Scientific Title**

Phase 1 Trial: CSD241701

The full scientific title will be published within 30 months after the end of the trial

Study objectives

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 18/07/2024, Office for Research and Ethics Committee Northern Ireland (Business Services Organisation Unit 4, Lissue Industrial Estate West, Rathdown Walk, Moira Road, Lisburn, Belfast, BT28 2RF, United Kingdom; +44 (0)28 9536 1400; info.orecni@hscni.net), ref: 24-NI-0077

Study design

Interventional single-centre randomized cross-over trial

Primary study design

Interventional

Study type(s)

Safety, Efficacy

Health condition(s) or problem(s) studied

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Other

Primary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date

26/08/2024

Eligibility**Key inclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

21 years

Upper age limit

60 years

Sex

All

Key exclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

19/07/2024

Date of final enrolment

19/08/2024

Locations

Countries of recruitment

United Kingdom

Northern Ireland

Study participating centre

Celerion Belfast

22-24 Lisburn Rd, Belfast

Belfast

United Kingdom

BT9 6AD

Sponsor information

Organisation

Reynolds American (United States)

ROR

<https://ror.org/05qcjd272>

Funder(s)

Funder type

Industry

Funder Name

Reynolds American Inc. Services

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to the protection of commercially confidential information

IPD sharing plan summary

Not expected to be made available